分化型甲状腺癌预后预测因素的回顾性队列研究及验证
该研究在澳大利亚一家四级中心回顾性分析2008至2016年间接受甲状腺切除术后放射性碘治疗的899例分化型甲状腺癌患者,建立预测同步转移/复发的风险模型,并在2017至2021年间393例患者中验证。多因素分析显示刺激后甲状腺球蛋白≥10 μg/L、甲状腺外侵犯和淋巴结受累预测复发,广泛甲状腺外侵犯、刺激后甲状腺球蛋白≥10 μg/L、多灶性乳头状甲状腺癌和滤泡状甲状腺癌与同步转移正相关。新模型通过纳入刺激后甲状腺球蛋白和甲状腺外侵犯修正并扩展了ATA危险分层。
要点
- 刺激后甲状腺球蛋白≥10 μg/L、甲状腺外侵犯和淋巴结受累是多因素分析中复发的预测因素。
- 独立于ATA分层,刺激后甲状腺球蛋白≥10 μg/L者无病生存期短于<10 μg/L者(p<0.001)。
- 按四种组织学分类分层的甲状腺外侵犯与更差的无病生存期显著相关(p<0.001)。
核心结论
- 新预测风险模型通过纳入刺激后甲状腺球蛋白和甲状腺外侵犯修正并扩展了ATA危险分层,二者被发现在分化型甲状腺癌中均为复发和同步转移的独立预测因素。
研究设计与样本
- 回顾性多变量分析,纳入2008至2016年间在澳大利亚一家四级中心接受甲状腺切除术后放射性碘治疗的899例患者,收集年龄、性别、组织学、刺激后甲状腺球蛋白和第8版美国癌症联合委员会(AJCC)分期,并回顾性计算ATA改良初始风险。
- 另用2017至2021年间接受放射性碘治疗的393例患者作为独立队列进行验证。
- 复发定义为需要手术干预或给予第二剂放射性碘活度的临床显著进展;同步转移定义为诊断时结构影像或初始碘治疗后扫描即存在的远处转移(即颈部以外)。
主要发现
- 多因素分析中,刺激后甲状腺球蛋白≥10 μg/L、甲状腺外侵犯和淋巴结受累预测复发。
- 独立于ATA分层,刺激后甲状腺球蛋白≥10 μg/L者无病生存期短于<10 μg/L者(p<0.001)。
- 按四种组织学分类分层的甲状腺外侵犯与更差的无病生存期显著相关(p<0.001)。
- 在部分患者中,甲状腺球蛋白抗体(TgAb)的存在不影响刺激后甲状腺球蛋白<10 μg/L患者的复发。
- 多因素分析中,广泛甲状腺外侵犯、刺激后甲状腺球蛋白≥10 μg/L、多灶性乳头状甲状腺癌和滤泡状甲状腺癌与同步转移正相关。
关键数值与推荐
- 复发预测因素:刺激后甲状腺球蛋白≥10 μg/L、甲状腺外侵犯、淋巴结受累。
- 同步转移正相关因素:广泛甲状腺外侵犯、刺激后甲状腺球蛋白≥10 μg/L、多灶性乳头状甲状腺癌、滤泡状甲状腺癌。
- 刺激后甲状腺球蛋白≥10 μg/L者无病生存期短于<10 μg/L者(p<0.001);甲状腺外侵犯按四种组织学分类分层与更差无病生存期相关(p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The goal of radioactive iodine (RAI) in differentiated thyroid cancer (DTC) is to treat metastasis and reduce recurrence risk. International guidelines provide broad risk stratification to aid treatment decisions, but a more nuanced approach to individualize care is warranted. We developed a predictive risk model for DTC. Methods: We performed a retrospective multivariable analysis of 899 patients who received RAI after thyroidectomy at a quaternary center in Australia between 2008 and 2016. Collected data included age, gender, histology, stimulated thyroglobulin (sTg), and 8th American Joint Committee Cancer (AJCC) staging. The ATA Modified Initial Risk (ATA) was calculated retrospectively. Recurrence was defined as clinically significant progression requiring either surgical intervention or administration of a second activity of RAI. Synchronous metastasis was defined as distant metastasis (i.e., outside of the neck) that was present at the time of diagnosis on structural imaging or initial post-iodine treatment scan. The features significantly associated with synchronous metastasis or recurrence were employed in the generation of a predictive risk model. A separate cohort of 393 patients who received RAI in 2017-2021 was used for validation. Results: On multivariate analysis, sTg ≥10 μg/L, extrathyroidal extension (ETE) and lymph node involvement predicted recurrence. Independent of ATA, patients with sTg ≥10 μg/L had a shorter disease-free survival (DFS) than those with sTg <10 μg/L (p < 0.001). The ETE stratified by four histological categories was significantly associated with worse DFS (p < 0.001). In a subset of patients, the presence of thyroglobulin antibody (TgAb) did not influence recurrence in patients with sTg <10 μg/L. On multivariate analysis, widespread ETE, sTg ≥10 μg/L, multifocal papillary thyroid cancer and follicular thyroid cancer were positively associated with synchronous metastasis. A predictive risk model was developed to estimate synchronous metastasis/recurrence risk and validated successfully in the second cohort. Conclusions: Our novel predictive risk model modifies and extends ATA stratification by including sTg and ETE, which we found to be independent predictors of both recurrence and synchronous metastasis in DTC.
引用
- Wijewardene A, Gill AJ, Gild M, et al. A Retrospective Cohort Study with Validation of Predictors of Differentiated Thyroid Cancer Outcomes. Thyroid. 2022. PMID: 35620896. doi:10.1089/thy.2021.0563
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。